Allied Market Research

2024

Pulmonary Hypertension Drug Market

Pulmonary Hypertension Drug Market Size, Share, Competitive Landscape and Trend Analysis Report by Product (Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase 5 Inhibitors, Soluble Guanylate Cyclase Stimulators) and by Application (Early stage Drug Candidates, Late stage Drug Candidates): Global Opportunity Analysis and Industry Forecast, 2023-2032

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Pulmonary hypertension is a state of the body in which the blood pressure rises in the arteries. Pulmonary hypertension drugs belong to the class of anti-hypertensives drugs that are used specifically to treat pulmonary hypertension. In addition, this class of drugs treats other life-threatening diseases such as arrhythmias, ryanoids syndrome, cephalagra, and angina.

Factors such as increase in geriatric population, healthcare expenditure, prevalence of hypertension, and healthcare awareness fuel the growth of the market. However, stringent government regulations and side-effects associated with the drugs such as hypotension, gastric ulcers, and congestive heart failure hinder the market growth. Ongoing R&D activities are anticipated to present new growth opportunities.

The market is segmented on the basis of product, application, and region. By product, the market is divided into prostacyclin & prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and soluble guanylate cyclase stimulators. Based on application, the market is categorized into early-stage drug candidates (phase I & phase II) and late-stage drug candidates (phase III & registration phase). By region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits

  • The study provides an in-depth analysis of the pulmonary hypertension drug market, with current trends and future estimations to elucidate investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
  • The report provides a quantitative analysis to help stakeholders to capitalize on prevailing market opportunities¬†in terms of value.
  • Extensive analysis of different segments helps understand various products of the market.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.

Pulmonary Hypertension Drug Market Report Highlights

Aspects Details
Pulmonary Hypertension Drug Market By Product
By Product
  • Prostacyclin and Prostacyclin Analogs
  • Endothelin Receptor Antagonists
  • Phosphodiesterase 5 Inhibitors
  • Soluble Guanylate Cyclase Stimulators
Pulmonary Hypertension Drug Market By Application
By Application
  • Early stage Drug Candidates
  • Late stage Drug Candidates
Pulmonary Hypertension Drug Market By Region
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players
Key Market Players

Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Abbott Laboratories, AstraZeneca plc, F. Hoffmann La Roche AG, Vectura Group plc, Novartis AG, GlaxoSmithKline plc, Merck and Co., Inc., Pfizer Inc.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Pulmonary Hypertension Drug Market

Global Opportunity Analysis and Industry Forecast, 2023-2032